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Abstract
Background: Retinal ganglion cells (RGCs) are responsible for the transmission of visual signals
to the brain. Progressive death of RGCs occurs in glaucoma and several other retinal diseases,
which can lead to visual impairment and blindness. Pigment epithelium-derived factor (PEDF) is a
potent antiangiogenic, neurotrophic and neuroprotective protein that can protect neurons from a
variety of pathologic insults. We tested the effects of PEDF on the survival of cultured adult rat
RGCs in the presence of glaucoma-like insults, including cytotoxicity induced by glutamate or
withdrawal of trophic factors.
Results: Cultured adult rat RGCs exposed to glutamate for 3 days showed signs of cytotoxicity
and death. The toxic effect of glutamate was concentration-dependent (EC50 = 31 μM). In the
presence of 100 μM glutamate, RGC number decreased to 55 ± 4% of control (mean ± SEM, n =
76; P < 0.001). The glutamate effect was completely eliminated by MK801, an NMDA receptor
antagonist. Trophic factor withdrawal also caused a similar loss of RGCs (54 ± 4%, n = 60, P <
0.001). PEDF protected against both insults with EC50 values of 13.6 ng/mL (glutamate) and 3.4 ng/
mL (trophic factor withdrawal), respectively. At 100 ng/mL, PEDF completely protected the cells
from both insults. Inhibitors of the nuclear factor κB (NFκB) and extracellular signal-regulated
kinases 1/2 (ERK1/2) significantly reduced the protective effects of PEDF.
Conclusion: We demonstrated that PEDF potently and efficaciously protected adult rat RGCs
from glutamate- and trophic factor withdrawal-mediated cytotoxicity, via the activation of the
NFκB and ERK1/2 pathways. The neuroprotective effect of PEDF represents a novel approach for
potential treatment of retinopathies, such as glaucoma.
Background
Glaucoma, one of the world's leading causes of visual
impairment and blindness [1], is characterized by excava-
tion of the optic nerve head and selective apoptotic loss of
retinal ganglion cells (RGCs), resulting in a progressive
decline in visual function. Elevated intraocular pressure is
a major risk factor for the development and progression of
glaucoma, although the loss of vision in glaucoma
patients does not always correlate with intraocular pres-
sure and lowering pressure sometimes does not com-
pletely impede the disease process [2-4]. Clearly, ocular
hypertension is not the exclusive cause of glaucomatous
retinopathy, and additional mechanisms likely play a role
in the degeneration of RGCs. In the past years, several
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additional mechanisms for glaucomatous optic neuropa-
thy and retinopathy have been proposed, including dis-
rupted retrograde transport of neurotrophic factors,
glutamate toxicity, retinal and/or optic nerve ischemia,
and immune abnormality [5-7]. These molecular events
can eventually lead to apoptosis of RGCs. Unfortunately,
the exact contribution of any of these factors in the patho-
genesis of glaucomatous damage has not been unequivo-
cally determined. It is probable that more than one
etiology and multiple mechanisms are responsible in dif-
ferent patients and in different stages of glaucoma.
Despite our incomplete understanding of the disease
processes and causes of RGC death, pharmacological pro-
tection of RGCs is under active investigation in ophthal-
mology research. Many neuroprotective strategies
designed to prevent or delay the degeneration of RGCs are
being evaluated, including some that are mechanism-spe-
cific. For example, glutamate receptor antagonists selec-
tively protect against glutamate-induced cytotoxicity and
may not have significant beneficial effects on other insults
potentially involved in glaucoma. In contrast, other
agents can protect RGCs against several toxic insults.
These compounds, with their broader protective spec-
trum, are likely more useful as therapeutic agents for glau-
coma. Pigment epithelium-derived factor (PEDF) appears
to be one of these agents.
PEDF is a 50-kDa protein initially isolated from fetal
human retinal pigment epithelial cells [8] and was later
found to be expressed in various ocular tissues and cells,
including the limbal region of the cornea and non-pig-
mented ciliary epithelial cells [9-12]. PEDF is also found
in the brain and spinal cord, as well as non-neuronal tis-
sues, such as endothelial cells and osteoblasts [13-15].
PEDF is a member of the serpin super-family of serine
protease inhibitors [16]. However, unlike many serpins,
PEDF does not inhibit serine proteases [17]. Instead, it
exhibits potent antiangiogenic, neurotrophic and neuro-
protective activities [13-15,18].
PEDF has broad neuroprotective effects in several neuro-
nal cells and tissues. PEDF reduces glutamate-induced
death of cerebellar granular cells, hippocampal neurons,
and spinal cord motor neurons [19-21]. It decreases post-
axotomy death of motor neurons and completely prevents
atrophy of the surviving neurons [20]. In the retina, PEDF
improves the survival of cultured mixed retinal cells under
oxidative stress [22]. It also protects against light-induced
damage to photoreceptor cells in vivo [23].
Intravitreal injection of recombinant PEDF or an adenovi-
ral vector expressing PEDF was demonstrated to reduce
retinal ischemia-induced RGC loss [24,25]. Although this
animal model may not be relevant to glaucoma per se, the
diverse protective effects of PEDF are nonetheless intrigu-
ing. We therefore tested PEDF in cultured adult rat RGCs
to further characterize its potential protective effects
against glaucoma-like insults.
Results
The adult rat retinal cell cultures using the method
described herein contained RGC-enriched retinal neu-
rons. More than 90% of the cells were positively labeled
with neuron-specific enolase antibody, indicating that the
majority of cells are neurons (data not shown). Approxi-
mately 20–30% of these cells expressed Thy-1, and all
Thy-1-positive cells were also positive for neurofilament-
L (Figure 1). Both Thy-1 and neurofilament-L are selective
cellular markers for RGC [26]. In contrast, cells in culture
did not express marker proteins for other retinal cell types:
they are negative for arrestin (photoreceptor), glial fibril-
lary acidic protein (GFAP; astroglia and Müller cell),
glutamine synthetase (Müller cell), or ED1 (microglia).
Less than 10% of the cells were labeled with the protein
kinase Cα antibody (rod bipolar cells) (data not shown).
Morphologically, the Thy-1-positive cells had the charac-
teristic appearance of neurons. After 2–3 days in culture,
neurite outgrowth typically had 2–4 main branches of
approximately 20–50 μm in length (Figure 2). As the cul-
ture period increased, the neurites lengthened and
became more extensive, with most spanning greater than
100 μm in length after 7 or 11 days in culture (Figure 2).
The RGCs appeared normal and healthy after 11 days in
culture. For the sake of convenience, however our cell sur-
vival assays were performed using 3-day cultures. Under
these conditions, there were 151 ± 7 Thy-1-positive cells/
well (mean ± SEM, n = 124). Treatment with glutamate,
an excitatory amino acid, damaged the cells. Glutamate
(100 μM) caused significant changes in the morphology
of many RGCs, including the loss of neurites, increased
number of vacuoles in the cytoplasm, and compromised
integrity of the plasma membrane (Figures 3A and 3B). In
addition, there was formation of a greenish autofluores-
cence in the dying/dead RGCs, which, combined with the
red fluorescent second antibody for Thy-1 detection,
appeared yellow or orange (Figure 3B). Glutamate signif-
icantly (P < 0.001) reduced the number of RGCs in culture
to 84 ± 6 cells/well (n = 76), corresponding to a 42% loss
of RGCs (35–55% loss among studies) compared to con-
trol samples (Figure 3C). Glutamate toxicity was concen-
tration-dependent with a calculated EC50  of 30.8 μM
(Figure 3D). MK801, an antagonist for the N-methyl-D-
aspartate (NMDA) glutamate receptor subtype, blocked
the glutamate toxicity in a dose-dependent manner (Fig-
ure 3E). At 100 nM, MK801 completely prevented cell loss
induced by 100 μM of glutamate. Agonists for non-NMDA
glutamate receptors, such as kainate (100 μM, selective forBMC Neuroscience 2007, 8:11 http://www.biomedcentral.com/1471-2202/8/11
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ionotropic AMPA/kainate receptors), quisqualate (100
μM, activates both AMPA/kainate and metabotropic
receptors), S-4-carboxy-3-hydroxyphenyl-glycine (50 μM,
Group I metabotropic receptor agonist), L-carboxycyclo-
propylglycine (10 μM, Group II metabotropic receptor
agonist), and L-(1)-2-amino-4-phosphonobutyrate (10
μM, Group III metabotropic receptor agonist) did not sig-
nificantly affect RGC survival (data not shown). Gluta-
mate toxicity appeared to be specific to the RGCs. At 100
μM, glutamate did not significantly affect Thy-1-negative
cells in culture (data not shown).
Incubation of the RGCs with PEDF dose-dependently
(EC50 = 13.6 ng/mL) protected against glutamate-induced
toxicity. Complete protection was achieved by 100 ng/mL
PEDF (Figure 4A). The same concentration of PEDF alone
did not affect RGC survival or normal cell morphology.
Although the PEDF receptor has not been well character-
ized, the biological effects of PEDF in other tissues and
cell types are known to be mediated by the nuclear factor
κB (NFκB) and/or extracellular signal-regulated kinases 1
and 2 (ERK1/2) cell signal transduction pathways [13-15].
Therefore, we evaluated the effects of inhibitors for these
pathways on the protective action of PEDF in our RGC
culture system. As shown in Figure 4B, the PEDF-medi-
ated RGC protection against glutamate toxicity was abol-
ished by either NFκB-SN50, a cell-permeable NFκB
inhibitor peptide, or ERK1/2 inhibitors, PD98059, SL327
and U0126. The effects of NFκB-SN50 and PD98059 were
concentration-dependent (Figures 4C and 4D). At the
highest concentrations tested, these two compounds
alone did not affect RGC survival (data not shown).
In addition to glutamate, the survival of RGCs in culture
was also sensitive to trophic factor withdrawal. Removal
of brain-derived neurotrophic factor (BDNF), basic
fibroblast growth factor (bFGF), ciliary neurotrophic fac-
tor (CNTF), and forskolin from the culture media for three
days caused a significant (P < 0.001) loss of RGCs, such
that only 82 ± 6 cells/well (n = 60) remained, which cor-
Identification of cultured adult rat RGCs Figure 1
Identification of cultured adult rat RGCs. Cultured cells were co-labeled with anti-Thy-1 antibody (A), anti-NF-L anti-
body (B), and DAPI (C). (D) A digitally merged image simultaneously represents all three fluorescent labels. (E) The corre-
sponding phase-contrast image. The cells were cultured for 3 days under control conditions. Scale bar = 50 μm.BMC Neuroscience 2007, 8:11 http://www.biomedcentral.com/1471-2202/8/11
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Morphology of cultured adult rat RGCs Figure 2
Morphology of cultured adult rat RGCs. The cells, cultured for 3 (A & B), 7 (C & D), and 11 (E & F) days, were labeled 
with anti-Thy-1 antibody (red) and DAPI nuclear stain (blue). (B), (D), are (F) are the corresponding phase-contrast images. 
Scale bar = 50 μm.BMC Neuroscience 2007, 8:11 http://www.biomedcentral.com/1471-2202/8/11
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Effect of glutamate on RGC morphology and survival Figure 3
Effect of glutamate on RGC morphology and survival. Cells were treated with glutamate or vehicle for 3 days. (A and 
B) Morphology of RGCs with glutamate (100 μM) treatment. (A) The cells were labeled with anti-Thy-1 antibody (red) and 
DAPI nuclear stain (blue). (B) The corresponding phase-contrast image. (C) Effect of glutamate (100 μM) on RGC survival (n = 
76). *** represents P < 0.001 vs. the control group by Student's t-test. (D) Concentration-dependent toxicity of glutamate on 
cultured RGCs (n = 6). * represents P < 0.05 vs. the control group by One-way ANOVA then Dunnett's test. (E) Effect of 
MK801 on glutamate-induced RGC toxicity. Cells were treated with the indicated concentrations of MK801 in the presence of 
100 μM of glutamate (n = 6). * represents P < 0.05 vs. the glutamate alone group by One-way ANOVA then Dunnett's test. 
Cell survival in (C), (D), and (E) was assessed by manually counting the Thy-1-positive cells. Data are presented as mean ± SEM.
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responded to an average 47% RGC loss compared to con-
trols. PEDF effectively protected the RGC against this
insult in a concentration-dependent manner with a calcu-
lated EC50 of 3.4 ng/mL (Figure 5A). The PEDF protective
effect on trophic factor withdrawal was also fully blocked
by NFκB-SN50 and ERK1/2 inhibitors (Figures 5B, 5C,
and 5D), similar to its effect against glutamate toxicity.
Discussion
We have shown that glutamate was toxic to adult rat RGCs
in culture, resulting in increased numbers of cells with
aberrant morphology and decreased total numbers of sur-
viving cells. This finding is similar to reports of glutamate
toxicity in many other neurons. Glutamate is known to
activate the NMDA, AMPA/kainite, and metabotropic
glutamate receptors. Although RGCs express all of these
receptor subtypes, the glutamate toxicity in our cultured
RGC model is primarily mediated by NMDA receptors,
because the NMDA receptor-specific antagonist MK801
blocked the response Agonists for the other glutamate
receptors did not seem to be lethal to the cells. These
results corroborate previous findings that the NMDA
receptor is important for excitotoxicity in RGCs [27,28].
Nevertheless, because of controversies regarding gluta-
mate-induced RGC toxicity, these data contradict other
published findings. For example, some reported that both
NMDA and kainite receptors contribute to RGC death
(e.g., reference [29]), while others showed that only the
kainite and not the NMDA receptor is responsible for RGC
toxicity (e.g., reference [30]). Yet another group of investi-
Protective effect of PEDF against glutamate-induced RGC toxicity Figure 4
Protective effect of PEDF against glutamate-induced RGC toxicity. (A) Cells were treated with the indicated concen-
trations of PEDF in the presence or absence of 100 μM of glutamate (n = 6). (B) Effects of various compounds on PEDF protec-
tion against excitotoxicity. Numbers on the bars represent sample sizes. (C and D) Concentration-dependent reversal of the 
PEDF protection by NFκB inhibitor NFκB-SN50 and ERK1/2 inhibitor PD98059, respectively. * represents P < 0.05 vs. the 
respective control group by One-way ANOVA then Dunnett's test. Glu = glutamate.
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gators demonstrated that RGCs are resistant to glutamate
or NMDA toxicity (e.g., reference [31]). The exact reasons
for these disparities are not fully understood, but could be
due to the different study conditions, which include the
age and species of animals used, the presence or absence
of other retinal cells in culture, or the duration and con-
centration of drug treatment. For example, in studies
where excitotoxicity was not obvious, the incubation time
was typically shorter (usually less than 24 h)[31] than that
when excitotoxicity was observed (3 days in the current
study)[27].
We also found that neurotrophic factors were essential for
the survival of cultured RGCs. Numerous previous studies
indicated that BDNF [32,33], CNTF [32,33], and bFGF
[34] are essential survival factors. However, other trophic
factors, such as nerve growth factor, glial cell line-derived
neurotrophic factor, neurotrophins-3 and -4, have also
been shown to be beneficial (reviewed in [35]). In the cur-
rent cell culture, removal of BDNF, CNTF, and bFGF sig-
nificantly reduced the survival of RGCs. Preliminary
studies suggest that among these three trophic factors
BDNF, in the presence of forskolin, was the most impor-
tant for the health of the RGCs (unpublished observa-
tion).
Interestingly, not all RGCs were damaged by either type of
insult in our culture system. Only about half of the RGCs
Protective effect of PEDF against trophic factor withdrawal-induced RGC toxicity Figure 5
Protective effect of PEDF against trophic factor withdrawal-induced RGC toxicity. (A) Cells were treated with the 
indicated concentrations of PEDF in the presence or absence of trophic factors (n = 6). (B) Effects of various compounds on 
the PEDF protection against trophic factor withdrawal-induced cytotoxicity. Numbers on the bars represent sample sizes. 
TFW = trophic factor withdrawal. (C and D) Concentration-dependent reversal of the PEDF protection by NFκB inhibitor 
NFκB-SN50 and ERK1/2 inhibitor PD98059, respectively. Three trophic factors, bFGF, BDNF, and CNTF were removed from 
the culture medium in the trophic factor withdrawal group. * represents P < 0.05 vs. the respective control group by One-way 
ANOVA then Dunnett's test.
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were lost after either glutamate treatment or trophic factor
withdrawal. Even with higher concentrations of glutamate
or longer incubation times, we still did not observe a com-
plete loss of the cells. Similar partial loss has been
reported previously [27,29,36-40]. It is not clear if the
neurons remaining after these insults differed biologically
and functionally from those that perished. Dreyer and co-
workers suggested that larger RGCs are more sensitive to
glutamate toxicity [36]. However, we did not detect any
size preferences of RGCs in susceptibility to either of the
insults (unpublished observation).
PEDF protected cultured RGCs against both excitotoxicity
and trophic factor withdrawal-induced cytotoxicity. Com-
plete protection was observed at 100 ng/mL, a concentra-
tion shown to be neurotrophic and neuroprotective in
other neurons [22,41,42]. This neuroprotective concen-
tration of PEDF appears relevant because PEDF concentra-
tion in human vitreous and aqueous humor was
determined to be approximately 0.5 to 3 μg/mL [43-49].
If RGCs in the retina are also exposed to similar levels of
PEDF, PEDF may serve as one of the trophic factors that
help sustain the health of RGCs. Interestingly, PEDF levels
in aqueous humor of patients with advanced glaucoma
are only about half of that of control eyes [48]. If PEDF
levels in the vitreous and retina are also reduced in glau-
comatous patients, the RGCs may be more susceptible to
glaucomatous insults. The major sources of PEDF expres-
sion are in the retinal pigment epithelium, ciliary epithe-
lium, and cornea [13-15]. In addition, RGCs themselves
also make PEDF [10-12]. This locally produced PEDF may
act as an autocrine effector and provide neurotrophic sup-
port for the RGCs.
Similar to other trophic factors, PEDF is expected to exert
its biological effects by specifically binding and activating
one or more receptors. However, PEDF receptors have not
yet been fully characterized. Human retinoblastoma Y-79
cells, rat cerebellar granule neurons, cells in the ganglion
cell layer, and inner segments of photoreceptor cells of
bovine eyes have high affinity PEDF binding sites (Kd = 3
nM) [50]. Most recently, a PEDF-binding protein, named
PEDF-R, was identified from the pigment epithelium of
human retina [51]. PEDF binds to this protein specifically
and with high affinity. PEDF binding activates the protein
and stimulates its phospholipase A2 enzymatic activity
[51]. Currently, it is unclear whether PEDF-R is the only
PEDF receptor subtype in the retina. Furthermore, its rela-
tionship to the cell signaling pathways responsible for the
biological activity of PEDF is yet to be determined.
Despite our incomplete knowledge of the PEDF receptor,
the NFκB and ERK1/2 pathways appear to be involved in
PEDF's activities [13-15]. Our studies with cultured RGCs
also indicate that both pathways are essential for the neu-
roprotective effects of PEDF. Inhibition of either pathway
was sufficient to abolish the protective effects of PEDF.
Activation of the transcription factor NFκB induces
expression of other neurotrophic factors, such as BDNF
and nerve growth factor, as well as antiapoptotic genes,
including Bcl2, Bcl-x, and superoxide dismutase [52,53].
ERK1/2 activation leads to modulation of other kinases,
phosphatases, transcription factors, and regulators of
apoptosis [54,55]. The identification of the down-stream
effectors involved in the PEDF protection of RGCs awaits
further studies.
The in vitro protective effects of PEDF suggest that PEDF
may also protect RGCs in vivo. Indeed, intravitreal injec-
tion of PEDF significantly, albeit partially, protected
against RGC loss and thinning of the inner retinal layers
due to transient retinal ischemia in the rat [24]. Similar
protection against the same insult and a reduction in
apoptosis of the RGC were observed when adenoviral vec-
tor encoding PEDF was injected intravitreally [25]. Our
results, together with these in vivo studies, suggest that
PEDF is a potent and efficacious protectant for RGCs.
PEDF should be a novel and effective therapeutic agent for
glaucoma and other neuroretinopathies associated with
RGC damage, provided obstacles to its delivery and
metabolism can be overcome.
Conclusion
Pigment epithelium-derived factor potently and effica-
ciously protects cultured adult rat RGC against glutamate-
or trophic factor withdrawal-induced cytotoxicity. The
protective effects of PEDF were mediated by activation of
NFκB and ERK1/2 pathways. This neuroprotective effect
of PEDF may lead to a novel approach for the treatment
of retinopathies, such as glaucoma.
Methods
Retinal cell culture
Handling of animals in this study was conducted in
accordance with the policies for use of animals in neuro-
science research established by the Society for Neuro-
science and by the Animal Care and Use Committee in
Alcon. Isolation of retinal cells was modified from a pre-
viously reported procedure [27]. Briefly, adult Sprague-
Dawley rats were euthanized by CO2 asphyxiation and
their eyes enucleated. The retina from each eye was dis-
sected and incubated in a papain solution, containing 2
mg/mL papain (Sigma, St. Louis, MO), 0.4 mg/mL DL-
cysteine (Sigma), and 0.4 mg/mL bovine serum albumin
(Sigma) in Neurobasal medium (Gibco/Invitrogen,
Carlsbad, CA), for 25 min at 37°C, then washed 3 times
with RGC culture medium [56] (Neurobasal/B27
medium containing 100 units/mL penicillin (Sigma), 100
μg/mL streptomycin (Sigma), 1 mM pyruvate (Gibco/Inv-
itrogen), 2 mM glutamine (Gibco/Invitrogen), 5 μg/mL
insulin (Sigma), 100 μg/mL transferrin (Sigma), 100 μg/BMC Neuroscience 2007, 8:11 http://www.biomedcentral.com/1471-2202/8/11
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mL bovine serum albumin (Sigma), 60 ng/mL progester-
one (Sigma), 16 μg/mL putrescine (Sigma), 40 ng/mL
sodium selenite (Sigma), 40 ng/mL thyroxine (Sigma), 40
ng/mL tri-iodothyronine (Sigma), 50 ng/mL BDNF (Bio-
source, Camarillo, CA), 10 ng/mL CNTF (Biosource), 10
ng/mL bFGF (Biosource), 5 μM forskolin (Sigma), and
1% fetal calf serum (Atlas Biologicals, Fort Collins, CO)).
Retinal pieces were triturated by passing through a fire-
polished disposable glass pipette until cells were dis-
persed. Cell density in the suspension was assessed with a
Coulter counter (Beckman Coulter, Fullerton, CA). 1 ×
106 to 3 × 106 cells/well were placed onto poly-D-lysine-
and laminin-coated 8-well chambered culture slides (sur-
face area = 0.69 cm2/well; Becton Dickinson, Franklin
Lakes, NJ) and cultured in 95% air/5% CO2 at 37°C.
Immunofluorescence
Cells were fixed with 3.7% formaldehyde in phosphate
buffered saline (PBS)(EMD Chemicals, Gibbstown, NJ) at
room temperature for 30 min, rinsed in PBS (Gibco) three
times, and incubated for 1 h with PBS containing 0.02%
saponin (Sigma) and the appropriate primary antibodies:
Thy-1 (1:500; Chemicon, Temecula, CA), neurofilament-
L (NF-L; 1:200; Serotec, Raleigh, NC), neuron-specific
enolase (1:200; Chemicon), arrestin (1:200; Abcam,
Cambridge, MA), protein kinase Cα (1:250; Oxford Bio-
medical Research, Oxford, MI), GFAP (1:500; Chemicon),
glutamine synthase (1:500; Sigma), or ED1 (1:100; Santa
Cruz Biotechnology). The primary antibody was then
removed, cells rinsed again, and incubated for 30 min
with fluorescence-labeled secondary antibodies (1:300),
Alexa fluor 594-labeled goat anti-mouse IgG (Invitrogen/
Molecular Probes, Carlsbad, CA), Oregon green-labeled
goat anti-rabbit IgG (Invitrogen/Molecular Probes), or
Alexa fluor 488-labeled rabbit anti-goat IgG (Invitrogen/
Molecular Probes). The cells were subsequently incubated
with DAPI solution (100 ng/mL; Sigma) for 5 min to stain
their nuclei. The slides were rinsed with distilled water,
covered with Fluoromount G (Southern Biotech, Birming-
ham, AL) and a cover glass (VWR, Westchester, PA). The
retinal cells was examined by fluorescence microscopy
and digital images obtained.
Cytotoxic insults
For glutamate-induced toxicity studies, cells were pre-
treated with vehicle or the indicated compounds for 30
min, followed by L-glutamate (0–1000 μM) (Sigma) for 3
days. For trophic factor withdrawal studies, three trophic
factors, bFGF, BDNF, and CNTF, together with forskolin,
were removed from the culture medium. Cells were cul-
tured in this medium for 3 days.
Quantification of cell survival
At the end of the incubation period, the cells were fixed
then labeled for Thy-1 and DAPI. RGC survival was quan-
tified by manually counting Thy-1-positive healthy cells
in each well.
Statistical analysis
Cell counts are expressed as mean ± SEM. Two-tailed Stu-
dent's t-test was used to compare between two groups.
One-way ANOVA followed by Dunnett's test was used to
compare among three or more study groups. P < 0.05 is
regarded as statistically significant.
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